Last A$0.31 AUD
Change Today -0.02 / -6.06%
Volume 130.5K
As of 12:45 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

ellex medical lasers ltd (ELX) Snapshot

Open
A$0.33
Previous Close
A$0.33
Day High
A$0.33
Day Low
A$0.31
52 Week High
01/22/14 - A$0.47
52 Week Low
11/4/13 - A$0.28
Market Cap
33.4M
Average Volume 10 Days
21.4K
EPS TTM
A$0.0076
Shares Outstanding
107.6M
EX-Date
12/3/02
P/E TM
40.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for ELLEX MEDICAL LASERS LTD (ELX)

Related News

No related news articles were found.

ellex medical lasers ltd (ELX) Related Businessweek News

No Related Businessweek News Found

ellex medical lasers ltd (ELX) Details

Ellex Medical Lasers Limited designs, manufactures, markets, and sells lasers and ultrasound systems for ophthalmologists to diagnose and treat eye diseases. The company offers selective laser trabeculoplasty (SLT)/YAG combination laser systems for the SLT treatment in glaucoma patients under the Tango and Solo names: iTRACK 250 microcatheter for the treatment of open-angle glaucoma; and Ultra Q Reflex, a multi-modality YAG laser with intraocular lenses (IOL), peripheral iridotomy for glaucoma, and YAG laser vitreolysis for the treatment of floaters. It also provides capsulotomy Ultra Q Reflex multi-modality YAG laser for the treatment of vitreous strands and opacities; Ultra Q, a microsurgical YAG laser for IOL-friendly photodisruption; and Super Q, a YAG laser to correct myopia or hyperopia. In addition, the company offers photocoagulators, including Solitaire, a portable green laser for the treatment of retinal disease; Integre Pro, a laser for use in the diagnosis and treatment of retinal disease; and Rapide, a pattern scanning photocoagulator. Further, it provides Eye Cubed, a diagnostic ultrasound system for the posterior and anterior segments of an eye. Additionally, the company is developing Retinal Rejuvenation Therapy, a non-thermal laser therapy for the treatment of diabetic retinopathy and age-related macular degeneration. It also offers a range of third-party medical devices and technologies. The company sells its products directly to end-user customers, as well as through independent third-party distributors in Australia, the United States, Europe, the Middle East, Asia, South America, and internationally. Ellex Medical Lasers Limited is headquartered in Adelaide, Australia.

221 Employees
Last Reported Date: 08/28/14

ellex medical lasers ltd (ELX) Top Compensated Officers

Group Chief Executive Officer
Total Annual Compensation: A$248.2K
Founder, Executive Chairman, Technical Direct...
Total Annual Compensation: A$45.0K
Vice President of Adavnced Research
Total Annual Compensation: A$180.9K
Compensation as of Fiscal Year 2014.

ellex medical lasers ltd (ELX) Key Developments

Ellex Medical Lasers Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Ellex Medical Lasers Limited reported audited consolidated earnings results for the year ended June 30, 2014. For the year, the company reported revenue of AUD 54,378,000 against AUD 42,804,000 a year ago. Profit from before income tax was AUD 1,311,000 against AUD 140,000 a year ago. Profit attributable to members of the parent was AUD 788,000 against loss attributable to members of the parent of AUD 816,000 a year ago. Basic and diluted earnings per share were 0.73 cents against basic and diluted loss per share of 1.0 cents a year ago. Net cash provided by operating activities was AUD 2,704,000 against AUD 1,944,000 a year ago. Payment for acquisition of business was AUD 1,693,000. Payment for property, plant and equipment was AUD 1,017,000 against AUD 605,000 a year ago. Payment for intangible assets was AUD 80,000 against AUD 78,000 a year ago.

Ellex Medical Lasers Limited Announces Further Results for 2RT Treatment of Early AMD

Ellex Medical Lasers Limited announced the 24-month follow up of the pilot study to investigate the efficacy of the company's proprietary Retinal Rejuvenation Therapy (2RT) in the treatment of early Age-Related Macular Degeneration (AMD) has been released and published in a summary form at the recent Association for Research in Vision and Ophthalmology (ARVO) 2014 conference in Orlando, Florida. This 24-month data, presented as a scientific poster on 9 May 2014 at ARVO by Associate Professor Erica L Fletcher MScOptom, PhD, Department of Anatomy and Neuroscience, The University of Melbourne, is a follow up to the 12-month data for the "2RT for Early AMD" pilot study (ACTRN 1260900E1056280) that was conducted over 2009 to 2011 at the Centre for Eye Research Australia (CERA) under Professor Robyn Guymer, MB, BS PhD, FRANZCO, Head of Macular Research at CERA. In the pilot study, 51 patients with intermediate AMD received a single treatment to one eye with the 2RT laser. Drusen area in each eye was graded at baseline, 12 and 24 months later. Changes in drusen area in the treated eyes were compared with a natural history AMD cohort of similar age range and clinical AMD severity. Drusen are a key important risk factor for progression of AMD to its blinding end stage. The 2RT laser treatment reduced drusen area in 35-40% of eyes following twelve and 24 months (compared to 5-11 % of eyes in a natural history cohort). This is consistent with the outcome of the 12-month data. Unlike currently marketed AMD treatments, which only address advanced or late-stage complications of the disease, Ellex's 2RT technology is designed to offer treatment earlier in the disease process, with the aim of slowing or reversing its progression. Pre-clinical studies were also conducted by A/Professor Fletcher to validate a mouse model of AMD and compare it with human data.

Ellex Medical Lasers Limited Reports Earnings Results for the Six Months Ended December 31, 2013; Provides Sales Guidance for the Second Half of 2014

Ellex Medical Lasers Limited reported earnings results for the six months ended December 31, 2013. For the period, the company reported EBITDA of $1.4 million against $0.9 million a year ago. EBIT was $1.2 million against $0.2 million a year ago. Reported NPAT was $0.4 million against $0.1 million a year ago. EPS was 0.36 cents against 0.04 cents a year ago. Underlying EBITDA of approx. $1.9 million, up 110% on pcp. Net cash flow was $3.6 million. Sales continue to accelerate with 8 month year to date sales growth of +21% on pcp vs first half growth of 17.7%. This trend is expected to continue for the remainder of second half of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELX:AU A$0.31 AUD -0.02

ELX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Carl Zeiss Meditec AG €20.77 EUR 0.00
Iridex Corp $7.33 USD +0.09
Synergetics USA Inc $3.39 USD 0.00
Topcon Corp ¥2,340 JPY -33.00
View Industry Companies
 

Industry Analysis

ELX

Industry Average

Valuation ELX Industry Range
Price/Earnings 41.8x
Price/Sales 0.6x
Price/Book 0.9x
Price/Cash Flow 14.9x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELLEX MEDICAL LASERS LTD, please visit www.ellex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.